On October 4, 2022 RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform, reported management’s participation in two upcoming investor conferences this month (Press release, Renovorx, OCT 4, 2022, View Source [SID1234621694]). Conferences include ROTH Inaugural Healthcare Opportunities, October 6th, and LD Micro Main Event XV, October 25th-27th.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Shaun Bagai, RenovoRx’s CEO, will provide a corporate update during his presentations. He will also discuss current available treatment options for pancreatic tumors, why they can fall short of providing an effective solution for treating this deadly disease, and how RenovoRx’s therapy platform re-envisions the treatment of pancreatic and other difficult-to-treat cancers. During the Conferences, Shaun will participate in one-on-one meetings with the investment community. Attendees include public companies, and institutional and private investors. To schedule a meeting, please reach out to your conference representative or send an email to KCSA Strategic Communications at [email protected].

ROTH Inaugural Healthcare Opportunities Conference

LD Micro Main Event XV